Partnership terminations, government investigations, pipeline updates, and advancements in new products mark this week’s earnings reports from Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Inovio Pharmaceuticals  Inc (NASDAQ:INO), MannKindCorporation (NASDAQ:MNKD), and Oracle Corporation (NYSE:ORCL).

Valeant Pharmaceuticals Intl Inc

Valeant is set to release its Q4:15 earnings on Tuesday, March 15 before market open. The company was originally supposed to release earnings on February 29, though announced it would delay the earnings release and pulled 2016 revenue guidance upon the return of CEO Michael Pearson, who has been hospitalized with pneumonia since December. A week prior to original earnings, the company announced it was delaying the SEC filing of its annual report and planned on restating some of its 2014-2015 revenues and earnings to reflect unaccounted for Philidor sales; a partnership which ended in October. Following Pearson’s return, the company announced it is under investigation by the SEC due to its questionable relationship with Philidor, but could not provide more details at the time. News of the investigation triggered an 18% drop in shares.

For the fourth quarter, analysts are expecting revenues of $2.75 billion and earnings of $2.61 per share, compared to revenues of $2.28 billion and earnings of $2.58 per share for the same quarter of last year. In the fourth quarter, the company was mostly focused on damage control regarding its decision to terminate relations with specialty pharmacy Philidor amidst fraud allegations. Like many other pharma giants, the company was subject to a congressional probe regarding its exceedingly high prices for Hep C drugs Harvoni and Sovaldi, retailing at over $80,000 per regimen. Accusations included purposefully limiting patient access to the drug and passing the high costs on to federal and state health care programs.

Following the cancellation of the earnings report and withdrawal of guidance, analyst Irina Rivkind Koffler of Mizuho weighed in on the stock, reiterating a Neutral rating and $112 price target on March 8, 2016. The analyst cited uncertainty regarding the Walgreens deal, allegations of questionable business practices, and CEO Pearson’s return. She also states that investors should “brace themselves for an entirely new story” upon the company’s earnings release.